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Abstract 
Burkholderia cenocepacia and other members of the Burkholderia cepacia complex (Bcc) are 
highly multidrug-resistant bacteria that cause severe pulmonary infections in patients with cystic 
fibrosis. A screen of 2686 compounds derived from marine organisms identified molecules that 
could synergize with polymyxin B to inhibit growth of B. cenocepacia. At 1 µg/ml, five 
compounds synergized with polymyxin B and inhibited the growth of B. cenocepacia by more 
than 70% compared to growth in polymyxin B alone. Follow-up testing revealed that one 
compound from the screen, the aminocoumarin antibiotic novobiocin, synergized with 
polymyxin B and colistin against tobramycin-resistant clinical isolates of B. cenocepacia and 
Burkholderia multivorans. In parallel, we show that novobiocin sensitivity is common among 
Bcc species and these bacteria are even more susceptible to an alternative aminocoumarin, 
clorobiocin, which also had an additive effect with polymyxin B against B. cenocepacia. These 
studies support using aminocoumarin antibiotics to treat Bcc infections and show that 
synergizers can be found to increase the efficacy of antimicrobial peptides and polymyxins 
against Bcc bacteria. 
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1. Introduction 
The alarming increase in multidrug resistance [1], particularly intrinsic, high-level resistance, 
undermines new treatments improving health and extending the life of patients with chronic 
conditions. For example, respiratory failure secondary to chronic pulmonary bacterial infection 
in patients with cystic fibrosis (CF) hinders the improvements in survival achieved over the last 
several decades and remains the primary cause of death [2]. The emergence of a growing number 
of CF pathogens with intrinsic, multidrug resistance such as Burkholderia cepacia complex 
(Bcc) bacteria, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and nontuberculous 
mycobacteria creates a pressing need for novel therapies [2]. The growing number of multidrug 
resistant bacteria and the lack of new antibiotics to combat them have led to the revival of the 
polymyxins, a family of lipid-linked antimicrobial peptides, as a last resort treatment despite 
their previously reported systemic toxicity [3]. Unfortunately, Bcc bacteria are also resistant to 
these compounds [3, 4]. We investigated therapeutic strategies to disrupt the high-level, intrinsic, 
multidrug resistance of B. cepacia complex, using Burkholderia cenocepacia as a model 
bacterium. B. cenocepacia is an environmental, opportunistic pathogen that belongs to the Bcc 
and causes serious respiratory infections in CF patients [5]. These infections are associated with 
faster decline in lung function, debilitating exacerbations and ultimately death [6], and they also 
reduce the survival of CF patients after lung transplant [7]. 
Antimicrobial adjuvants are molecules that inhibit a bacterial resistance mechanism to an 
antibiotic, effectively increasing the bacterial susceptibility to that antibiotic [8]. This concept 
has been investigated as an appealing approach to reverse resistance of bacteria to antibiotics [9]. 
Here, we used a strategy to identify compounds that synergize with polymyxin B against B. 
cenocepacia by screening a library of naturally occurring molecules derived from marine 
sources. These synergists reduce the extreme resistance of B. cenocepacia and other Bcc bacteria 
towards polymyxin B (PmB) and colistin (polymyxin E), thereby increasing their antimicrobial 
effectiveness. Clinically, this could provide an effective way to reduce the dosage of polymyxins 
and therefore increase their efficacy while at the same time overcoming their toxic effects. 
 
2. Materials and Methods  
2.1. Bacterial strains. 
 B. cenocepacia K56-2 was used in the initial screen; this isolate is from a CF patient and 
is commonly used as prototypic strain from the B. cenocepacia ET-12 epidemic clonal lineage. 
Follow-up studies were conducted using the previously described Bcc strain panel [10], as well 
as two tobramycin-resistant B. cenocepacia CF isolates (GIB-C1141144 and GRI-C1210932). 
 
2.2. Screening a library of compounds for synergism with PmB. 
The library consisted of 2,686 compounds derived from sea life, isolated and 
characterized by Biomar Microbial Technologies, Spain. Solutions of these compounds were 
seeded in pairs of 100-well Bioscreen C plates and the solvent was evaporated. Overnight 
cultures of K56-2 were diluted to an OD600 of 0.0002 in fresh LB medium and added to the plates 
(300 µl/well), dissolving the compounds to a final concentration of 1 µg/ml. Plate pairs were 
incubated in the Bioscreen C automated growth curve analyzer at 37oC with continuous medium 
shaking. After 2 h, PmB was added to one plate at a final concentration of 500 µg/ml and the 
vehicle control in which PmB is dissolved (0.2% bovine serum albumin, 0.01% acetic acid) was 
added to the other plate. This concentration of PmB has little impact on the growth of B. 
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cenocepacia K56-2 (data not shown). Wells with no compounds were also included in each plate 
of the pairs. The plates were further incubated at 37oC and the OD600 was read every 30 min. 
Further, one well on each plate had no compound and received sterile LB plus the vehicle control 
or PmB to provide a negative control and confirm that each experiment was performed 
aseptically. This experimental design allows the identification of compounds that have direct 
antimicrobial activity against B. cenocepacia as well as those that synergize with PmB.  
 
2.3. Minimum inhibitory concentration MIC and checkerboard assays. 
MIC assays were conducted as previously described [11]. The incubation time for GIB-
C1141144 and GRI-C1210932 was extended to 48 h, as these strains grow much slower than 
K56-2.  Checkerboard assays were conducted with combinations of antibiotics. When the MIC 
values could be determined (novobiocin, clorobiocin, and tobramycin) increasing concentrations 
in two-fold increments between 1/32 of the MIC value and the MIC value were used. For 
example, if the novobiocin MIC of a particular strain is 16 µg/ml, 0.5, 1, 2, 4, 8, and 16 µg/ml 
were tested in the checkerboard assay. Accurate polymyxin B and colistin MIC values against 
Bcc bacteria cannot be determined because these bacteria grow at concentrations greater than the 
solubility of these compounds in growth medium. All Bcc strains grew in 1024 µg/ml polymyxin 
B and colistin, the highest concentrations tested. These were considered to be half the MIC value 
for all of the Bcc strains examined. In checkerboard assays, polymyxin B and colistin were tested 
at concentrations of 64 (1/32 MIC), 128 (1/16 MIC), 256 (1/8 MIC), 512 (1/4 MIC), and 1024 
µg/ml (1/2 MIC). Fractional inhibitory concentration (FIC) indices were calculated as FIC = 
A/MICA + B/MICB where A and B are the concentrations of two antibiotics required in 
combination to inhibit the growth of the bacteria and MICA and MICB are the MIC values for 
drugs A and B alone [12]. An FIC index ≤ 0.5 was considered synergistic. For synergy studies, 
all antibiotics came from independent suppliers: novobiocin (>90% pure), polymyxin B (>60% 
pure), colistin (>50% pure), and tobramycin (>98% pure) were purchased from Sigma. Rhone-
Poulenc Santé donated commercial-grade clorobiocin. Novobiocin and clorobiocin MIC values 
for the experimental Bcc strain panel were also determined using a conventional broth dilution 
approach [13]. MIC and checkerboard experiments were independently repeated up to 4 times. In 
cases where multiple values were obtained between replicates, we reported the larger (more 
conservative) value. 
 
3. Results 
 
3.1 Small molecule screening for polymyxin B synergizers 
None of the 2686 compounds from marine sources had significant inhibitory effects on 
the bacterial cells at the concentration tested (1 µg/ml) in the absence of PmB (Fig 1). The 
highest inhibition in the absence of PmB was 22.8%. Under these conditions, the hit rate for this 
library of compounds that directly inhibit B. cenocepacia strain K56-2 is 0% (0/2686). This does 
not preclude that they may possess direct antibiotic activity at higher concentrations. As 
described below, one of the compounds in the library was novobiocin and if the concentration of 
the library had been 20 µg/ml, bacterial growth inhibition in the absence of PmB would have 
been observed.	   
The screen revealed five compounds that were effective in potentiating the antimicrobial 
activity of PmB against B. cenocepacia K56-2 (Fig. 1). The combination of each of them with 
PmB inhibited growth by 70% or more relative to growth in PmB alone at 20 h. The hit rate for 
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compounds that synergize with PmB was 1.9% (5/2686).	  These compounds are thielavin B (Fig. 
2A), micacocidin B (Fig. 2B), IKD-8344 (Fig. 2C), a novel compound CL0231 (Fig. 2D), and 
novobiocin (Fig. 2F). Three other compounds with structures similar to micacocidin B but not in 
complexes with metal were present in the library, but none of them had any synergistic effects 
with PmB against B. cenocepacia. This provides an internal control indicating that the metal in 
micacocidin B is required for its activity. A compound similar to CL0231 (CL0236, Fig. 2E) 
with a phenylalanine replacing a valine residue did not have any synergistic effects with PmB, 
suggesting that the bioactivity of CL0231 and related compounds depends on their amino acid 
sequences. Of these five compounds we confirmed the activity in follow-up studies for 
novobiocin and IKD-8344 (confirmation rate of 40%, 2/5), as we could not obtain sufficient 
amounts of the other three compounds to repeat the assays. 
 
3.2 Novobiocin and polymyxin B synergize against other Burkholderia isolates 
We evaluated whether the synergistic effect of novobiocin against B. cenocepacia K56-2 
also occurs in other clinical Bcc isolates (Burkholderia multivorans strain C0514 and two 
tobramycin-resistant Bcc isolates, GIB-C1141144 and GRI-C1210932). In addition to testing 
PmB, we included colistin and tobramycin in these studies since nebulized formulations of these 
antibiotics are used to treat pulmonary bacterial infections in CF patients [2]. We first 
determined the individual MIC values against these Bcc strains. All of them had novobiocin MIC 
values of 16 µg/ml, which were considerably lower than values for Pseudomonas aeruginosa 
PAO1 (512 µg/ml) and Escherichia coli DH5α (128 µg/ml). Bcc bacteria grew at the highest 
concentrations tested (1024 µg/ml) for PmB and colistin. Finally, Bcc isolates GIB-C1141144 
and GRI-C1210932 were considerably more resistant to tobramycin (MIC=2048 and 4096 µg/ml 
respectively) than either K56-2 or C0514 (MIC=256 µg/ml).  
 Checkerboard assays were performed to quantitate levels of synergism. Since the MIC 
values for all Bcc bacteria with PmB and colistin are greater than the highest concentration tested 
(1024 µg/ml), we empirically considered 1024 µg/ml to be one half the MIC value. Novobiocin 
acted synergistically with both PmB and colistin against the tested Bcc strains (Table 2). 
Synergism between novobiocin and antimicrobial peptides against Gram-negative bacteria has 
been previously reported [12]. Novobiocin slightly enhanced the activity of tobramycin against 
K56-2 and C0514, but the FIC indices were above 0.5 (Table 2). In contrast, sub-MIC 
concentrations of tobramycin antagonized the activity of novobiocin against the tobramycin-
resistant isolates GIB-C1141144 and GRI-C1210932 (FIC indices > 1). We speculate that sub-
MIC concentrations of tobramycin activate a mechanism in these strains that provides cross-
resistance against novobiocin. 
Similar experiments with other synergistic compounds detected from the initial screen 
were not possible due to our inability at this point to extract higher concentrations of these 
compounds from their marine sources and lack of alternative sources for most of the compounds. 
Fermentation of these compounds from their producer organisms, their overproduction from a 
recombinant expression system, or their chemical synthesis are possible options for further 
evaluation of these compounds in the future. 
 
3.3 Clorobiocin is more potent than novobiocin against Burkholderia bacteria and also 
enhances polymyxin B activity 
Given the synergism of novobiocin with polymyxin B, and the low MIC of novobiocin 
for K56-2, we investigated another aminocoumarin, clorobiocin (Fig. 2G). Clorobiocin was more 
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potent than novobiocin; its MIC against K56-2 was 1 µg/ml. A parallel experiment comparing 
the MIC values of the two aminocoumarins against the 30 strains of the Bcc panel [10] also 
showed that MIC values for clorobiocin were significantly lower than those for novobiocin 
(Table 2). The FIC value for clorobiocin and PmB against K56-2 was 0.515, indicating that these 
compounds have an additive effect and are close to the cut-off for synergism.  
 
4. Discussion 
There is great need for more effective antibiotics against non-fermenting opportunistic 
Gram-negative bacteria [2]. While polymyxins or other antimicrobial peptides represent an 
excellent choice, their high dosage to overcome high-level resistance in some of these bacterial 
species could be problematic due to toxicity and solubility of the peptides in biological solvents. 
The combination of polymyxins with synergistic molecules that can potentiate their antibacterial 
activity offers an opportunity for more effective treatments at lower dosages, which will carry a 
significant benefit to patients by reducing toxicity. In this work, we employed a screening 
strategy allowing us to detect compounds that synergize with PmB. Five such compounds were 
found in a library of 2686 compounds obtained from marine sources. This relatively high success 
ratio provides proof of concept that it is possible to find compounds that could synergize with 
antimicrobial peptides, reversing the resistance of Bcc bacteria against these last resort 
antibiotics. As an alternative to screening for antibiotic synergism, development of inhibitors 
targeting specific pathways involved in Bcc antibiotic resistance might also be an effective 
strategy for combating Bcc infection. In that context, efforts [23, 24] have been made to develop 
novel therapeutics that specifically target the synthesis pathways of two different components of 
the lipopolysaccharide molecule, both of which have been implicated in B. cenocepacia 
antimicrobial peptide resistance [25, 26]. Furthermore, recent observations point to alternative 
strategies inhibiting secreted molecules that communicate antibiotic resistance to other less 
resistant members of a bacterial population [27]. 
Four compounds (thielavin B, micacocidin B, IKD-8344, and CL0231) identified in the 
initial screen require further testing before firm conclusions about their synergy with PmB or 
other compounds can be made. Thielavin B (Fig. 2A) is a prostaglandin synthesis inhibitor 
produced by the fungus Thielavia terricola [14], that also interferes with peptidoglycan synthesis 
in Enterococcus faecalis [15]. Micacocidin B (Fig. 2B) is a copper-containing compound 
produced by Pseudomonas sp. with potent activity against various Mycoplasma species [16]. 
IKD-8344 (Fig. 2C) is a macrodiolide previously shown to be cytotoxic and anthelmintic [17]. 
The fourth compound was a novel cyclic peptide coded CL0231 (Fig.2 D).  
The fifth compound, novobiocin (Fig. 2F) is a bacteriostatic aminocoumarin antibiotic 
that binds to the B subunit of DNA gyrase (GyrB) blocking the ATPase activity and hence 
inhibiting DNA supercoiling [18]. It is active against Gram-positive organisms, with little 
activity against enteric Gram-negative bacilli [19]. In 2009, the U.S. Food and Drug 
Administration prevented use of novobiocin capsules on the market because of adverse reactions 
including relatively common skin reactions, jaundice, hepatic failure, and blood dyscrasias, as 
well as concerns about the development of novobiocin-resistant staphylococci during treatment 
and potential for drug interactions [20]. However, novobiocin is still used in veterinary as feed 
supplement for chickens and turkeys (U.S. Food and Drug Administration Code of Federal 
Regulations 21CFR558.415, Revised as of April 1, 2014), and topically for treatment of bovine 
mastitis in lactating cattle (licensed by the UK Veterinary Medicine Directorate). An alternative 
aminocoumarin, clorobiocin, had increased efficacy compared to novobiocin against Bcc 
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bacteria and also enhanced polymyxin B activity. Greater clorobiocin efficacy may be the result 
of stronger enzyme inhibition by clorobiocin as previously shown against the DNA gyrase and 
topoisomerase IV proteins from both E. coli and Staphylococcus aureus [21]. Alternatively, 
differences between novobiocin and clorobiocin might be due to other clorobiocin targets, for 
example clorobiocin can inhibit the phosphoserine phosphatase SerB2 of Mycobacterium 
tuberculosis while novobiocin cannot [22]. 
 The observation that novobiocin and clorobiocin at low concentrations synergize with 
PmB and colistin against Bcc isolates suggests that these combinations could be considered for 
treatment of these pan-antibiotic resistant bacteria. Recently, Moore et al. showed that 
novobiocin displayed potent antimicrobial activity against 20 B. cenocepacia CF isolates that are 
irresponsive to any other antibiotic [28]. In that study, 30 P. aeruginosa CF isolates were not 
affected by novobiocin. These observations agree with our data concerning the susceptibility of 
the different bacterial species to novobiocin. Safety concerns resulted in withdrawal of human 
use of novobiocin [20]; however, novel drug delivery systems based on a nebulized solution or a 
dry powder inhaler that would deliver enhanced concentrations of aminocoumarins locally could 
control systemic toxicity and treat Bcc infections [28]. We further suggest their use in 
combination with colistin due to the synergistic effects of both antibiotic classes against Bcc 
bacteria. This will also facilitate using lower doses of each antibiotic, reducing systemic toxicity. 
In addition, using aminocoumarin derivatives with enhanced potency against Bcc bacteria such 
as clorobiocin would allow further lowering the aminocoumarin concentration in the antibiotic 
combination. In conclusion, the results of this study, in addition to recent supporting evidence 
[28], warrant reconsideration of novobiocin, clorobiocin or other aminocoumarins for human use 
in combination with colistin administered by a novel delivery system to control infections by 
multidrug resistant Bcc bacteria. There are reports in the literature of select antimicrobial 
peptides with increased activity against Burkholderia sp. [29, 30] and the efficacy of these 
compounds in conjunction with an aminocoumarin would also be worth exploring. 
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Table 1: FIC indices for combinations of novobiocin with other antibiotics 
Species/strain FIC index for novobiocin + PmB Colistin Tobramycin 
B. cenocepacia K56-2 0.31 0.28 0.63 
B. multivorans C0514 0.28 0.5 0.63 
B. cenocepacia GIB-C1141144 0.5 0.56 >1.0 
B. cenocepacia GRI-C1210932  0.31 0.38 >1.0 
 
Table 2: Novobiocin and clorobiocin MIC distribution amongst Bcc bacteria 
MIC 
(µg/ml) 
Bcc isolates (30) 
Novobiocin Clorobiocin 
1 0 1 
2 1 0 
4 0 14 
8 0 12 
16 2 3 
32 12 0 
64 15 0 
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Legend to Figures 
Figure 1. Five compounds from the library of 2686 compounds showed synergistic effects with 
500 µg/ml PmB against B. cenocepacia K56-2. Results are shown as percentage inhibition of the 
growth in the presence of compounds relative to that in the absence of compounds whether alone 
(X-axis) or in combination with PmB (Y-axis). A black circle represents each compound. The 
red circle represents the results of all wells with no library compound added (1 well per plate). 
Compounds considered significantly inhibitory on their own or synergistic with PmB had to 
inhibit growth by more than 70% (dashed lines with shaded areas representing higher levels of 
inhibition). The dotted line has a slope of one and intersects with the origin; it is drawn for 
illustrative purposes only. Points in the upper left quadrant represent compounds that do not 
directly inhibit B. cenocepacia growth at the concentration tested but that synergize with 
PmB. Points in the lower right quadrant represent compounds that inhibit B. cenocepacia but are 
antagonized by PmB. Points near the line in the upper right quadrant represent compounds 
that inhibit B. cenocepacia but that do not increase or decrease the effect of PmB. The 
compounds are: A, IKD-8344; B, Novobiocin; C, CL0231; D, Micacocidin B; E, Thielavin B. 
Figure 2. Chemical structures of compounds discussed in the text. A, Thielavin B. B, 
Micacocidin B. C, IKD-8344. D, CL0231. E, CL0236. F, Novobiocin. G, Clorobiocin. Structures 
were drawn using Marvin Sketch Version 14.12.8. 
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Figure 1 
	   10	  
 
 
Figure 2 
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